Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers.
OBJECTIVE
To compare transient blood-brain barrier disruption (BBBD) by hypertonic mannitol with pharmacological modification of the blood-tumor barrier by the vasoactive peptide bradykinin for delivery of small and large agents to nude rat intracerebral xenografts.


METHODS
Female nude rats (n = 104) with 6-day intracerebral human small cell lung carcinoma tumors were treated using BBBD (n = 24), intracarotid bradykinin (n = 38), or saline (controls, n = 32) administered intra-arterially. During or immediately after infusion, the rats were given radiolabeled agent (methotrexate or dextran 70; Dupont NEN, Boston, MA). The rats were killed 10 minutes later, and samples of tumor and brain regions were obtained for scintillation counting. Twenty-two additional rats were examined using magnetic resonance imaging after administering one of two contrast agents (gadoteridol or iron oxide nanoparticles) or saline (controls) in conjunction with BBBD or bradykinin.


RESULTS
After BBBD, the delivery of both small (methotrexate) and large (dextran 70) radiolabeled tracers was increased 2- to 6-fold in the tumor and 3- to 20-fold in surrounding brain, as compared with saline controls. After bradykinin treatment, there was minimal change in delivery of methotrexate or dextran 70 to tumor and brain around tumor, with the greatest increase less than 60% over controls. Magnetic resonance imaging demonstrated increased delivery of both small and large contrast agents to the treated hemisphere after BBBD. In comparison, no increased tumor enhancement could be detected after bradykinin treatment.


CONCLUSIONS
BBBD resulted in global delivery of a variety of agents in a wide range of sizes. In this human brain tumor xenograft model, bradykinin was not effective at increasing delivery to the tumor of any agent tested.
Kroll
R A
RA
Department of Neurology, Oregon Health Sciences University, Portland, USA.
Pagel
M A
MA
Muldoon
L L
LL
Roman-Goldstein
S
S
Fiamengo
S A
SA
Neuwelt
E A
EA
D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects*; D001920:Bradykinin / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D001932:Brain Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000556:secondary; D018288:Carcinoma, Small Cell; D005260:Female; D006801:Humans; D006982:Hypertonic Solutions; D008175:Lung Neoplasms; D008353:Mannitol / Q000494:pharmacology*; D009368:Neoplasm Transplantation; D051381:Rats; D011923:Rats, Nude; D014407:Tumor Cells, Cultured
D006982:Hypertonic Solutions; D008353:Mannitol; D001920:Bradykinin